Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies

NCT04115267 · tracked via the Priya Life Science Canada tracker

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Phase

Observational

Started

2019-09-13

Last updated

2026-08-14

Condition(s) studied

CancerRadiotherapy Side Effect

Investigational drug(s) / intervention(s)

Radiotherapy

Radiotherapy: Combined modality

Study summary

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Consent to be part of the AtTRIBut registry * Prior histological diagnosis of primary cancer. * If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis * Age\> 18 years * Receiving a molecular therapy * Indicated to receive radiotherapy * Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques. Exclusion Criteria: • Refusal or inability to receive radiotherapy

Primary outcome measure(s)

Number of Participants with severe side effects — 1 year
CTCAE V5 Grade 3-5 toxicities

Trial sites (1)

Facility	City	Region	Status
Centre Hospitalier de l'Université de Montréal	Montreal	Quebec	Recruiting

More Centre hospitalier de l'Université de Montréal (CHUM) trials in Canada

Safety of PET MPI Using the CRCHUM N-13 Ammonia Recruiting

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface Recruiting

Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration Starting soon

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Starting soon

A Portable Thoracic Impedance Device for Detecting Pulmonary Congestion in Heart Failure Patients Recruiting

Other trials for the same condition

Adaptive RadioTherapy for OroPharynx Cancer Recruiting

Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2) Recruiting

Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study Starting soon

Childhood Cancer Survivor Study Recruiting

Pan Tumor Rollover Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04115267 on ClinicalTrials.gov ↗ ← All trials in Canada